MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Protagonist Therapeutics Inc

Deschisă

SectorSănătate

44.11 -2.5

Rezumat

Modificarea prețului

24h

Curent

Minim

43.34

Maxim

45.71

Indicatori cheie

By Trading Economics

Venit

165M

132M

Vânzări

166M

171M

P/E

Medie Sector

10.827

57.333

EPS

1.98

Marjă de profit

77.166

Angajați

126

EBITDA

168M

127M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+51.17% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

631M

2.8B

Deschiderea anterioară

46.61

Închiderea anterioară

44.11

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Protagonist Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mar. 2025, 13:59 UTC

Principalele dinamici ale pieței

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Comparație

Modificare preț

Protagonist Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

51.17% sus

Prognoză pe 12 luni

Medie 67.8 USD  51.17%

Maxim 82 USD

Minim 38 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruProtagonist Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

9

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

42.62 / 45.85Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.